Document 0595 DOCN M9490595 TI A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. DT 9411 AU Lunney EA; Hagen SE; Domagala JM; Humblet C; Kosinski J; Tait BD; Warmus JS; Wilson M; Ferguson D; Hupe D; et al; Parke-Davis Pharmaceutical Research, Division of Warner Lambert,; Ann Arbor, Michigan 48105-2430. SO J Med Chem. 1994 Aug 19;37(17):2664-77. Unique Identifier : AIDSLINE MED/94343455 AB HIV-1 protease has been identified as a significant target enzyme in AIDS research. While numerous peptide-derived inhibitors have been described, the identification of a nonpeptide inhibitor remains an important goal. Using an HIV-1 protease mass screening technique, 4-hydroxy-3-(3-phenoxypropyl)-2H-1-benzopyran-2-one (1) was identified as a nonpeptide competitive inhibitor of the enzyme. Employing a Monte Carlo-based docking procedure, the coumarin was docked in the active site of the enzyme, revealing a binding mode that was later confirmed by the X-ray crystal analysis. Several analogs were prepared to test the binding interactions and improve the overall binding affinity. The most active compound in the study was 4,7-dihydroxy-3-[4-(2-methoxyphenyl)butyl]-2H-1-benzopyran-2-one (31). DE Acquired Immunodeficiency Syndrome/DRUG THERAPY Binding Sites Comparative Study Coumarins/*CHEMISTRY/CHEMICAL SYNTHESIS/METABOLISM Crystallography, X-Ray Drug Design Human HIV Protease/*CHEMISTRY/METABOLISM HIV Protease Inhibitors/*CHEMISTRY/METABOLISM HIV-1/ENZYMOLOGY Models, Molecular Molecular Conformation Molecular Structure Monte Carlo Method Oligopeptides/CHEMISTRY/METABOLISM Protein Conformation 4-Hydroxycoumarins/*CHEMISTRY/METABOLISM JOURNAL ARTICLE SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).